A detailed history of Alpha Mark Advisors, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Alpha Mark Advisors, LLC holds 527 shares of ABBV stock, worth $92,314. This represents 0.04% of its overall portfolio holdings.

Number of Shares
527
Previous 524 0.57%
Holding current value
$92,314
Previous $90,000 15.56%
% of portfolio
0.04%
Previous 0.03%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$163.84 - $199.33 $491 - $597
3 Added 0.57%
527 $104,000
Q2 2024

Jul 17, 2024

SELL
$154.79 - $180.76 $10,216 - $11,930
-66 Reduced 11.19%
524 $90,000
Q1 2024

Apr 18, 2024

BUY
$159.82 - $182.1 $11,666 - $13,293
73 Added 14.12%
590 $107,000
Q4 2023

Jan 19, 2024

BUY
$137.6 - $154.97 $3,990 - $4,494
29 Added 5.94%
517 $80,000
Q3 2023

Oct 31, 2023

BUY
$133.59 - $154.65 $534 - $618
4 Added 0.83%
488 $73,000
Q2 2023

Jul 28, 2023

SELL
$132.51 - $164.9 $12,720 - $15,830
-96 Reduced 16.55%
484 $65,000
Q1 2023

May 04, 2023

SELL
$144.61 - $166.54 $6,652 - $7,660
-46 Reduced 7.35%
580 $92,000
Q4 2022

Feb 06, 2023

SELL
$138.31 - $165.87 $23,789 - $28,529
-172 Reduced 21.55%
626 $101,000
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $536 - $615
4 Added 0.5%
798 $107,000
Q2 2022

Aug 11, 2022

BUY
$137.62 - $174.96 $412 - $524
3 Added 0.38%
794 $122,000
Q1 2022

May 02, 2022

SELL
$131.98 - $163.75 $12,670 - $15,720
-96 Reduced 10.82%
791 $128,000
Q4 2021

Feb 09, 2022

SELL
$107.43 - $135.93 $15,684 - $19,845
-146 Reduced 14.13%
887 $120,000
Q3 2021

Nov 05, 2021

BUY
$106.4 - $120.78 $29,579 - $33,576
278 Added 36.82%
1,033 $111,000
Q2 2021

Aug 06, 2021

BUY
$105.21 - $117.21 $420 - $468
4 Added 0.53%
755 $85,000
Q1 2021

Apr 29, 2021

BUY
$102.3 - $112.62 $511 - $563
5 Added 0.67%
751 $81,000
Q4 2020

Feb 01, 2021

BUY
$80.49 - $108.67 $321 - $434
4 Added 0.54%
746 $79,000
Q3 2020

Nov 06, 2020

SELL
$85.91 - $100.83 $29,724 - $34,887
-346 Reduced 31.8%
742 $65,000
Q2 2020

Aug 10, 2020

BUY
$73.37 - $98.18 $36,978 - $49,482
504 Added 86.3%
1,088 $107,000
Q1 2020

Apr 24, 2020

BUY
$64.5 - $97.79 $258 - $391
4 Added 0.69%
584 $44,000
Q4 2019

Feb 07, 2020

BUY
$72.13 - $90.25 $288 - $361
4 Added 0.69%
580 $51,000
Q3 2019

Nov 01, 2019

SELL
$62.98 - $75.72 $198,575 - $238,745
-3,153 Reduced 84.55%
576 $44,000
Q2 2019

Aug 02, 2019

SELL
$65.7 - $83.98 $29,696 - $37,958
-452 Reduced 10.81%
3,729 $271,000
Q1 2019

May 09, 2019

BUY
$77.14 - $90.79 $6,634 - $7,807
86 Added 2.1%
4,181 $337,000
Q4 2018

Feb 06, 2019

BUY
$77.85 - $96.01 $389 - $480
5 Added 0.12%
4,095 $378,000
Q3 2018

Nov 05, 2018

SELL
$88.91 - $98.84 $17,337 - $19,273
-195 Reduced 4.55%
4,090 $387,000
Q2 2018

Aug 03, 2018

BUY
$89.78 - $106.23 $18,045 - $21,352
201 Added 4.92%
4,285 $397,000
Q1 2018

May 09, 2018

SELL
$92.01 - $123.21 $45,912 - $61,481
-499 Reduced 10.89%
4,084 $387,000
Q4 2017

Feb 09, 2018

SELL
$89.56 - $98.21 $31,256 - $34,275
-349 Reduced 7.08%
4,583 $443,000
Q3 2017

Nov 02, 2017

BUY
$69.85 - $89.22 $344,500 - $440,033
4,932
4,932 $438,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Alpha Mark Advisors, LLC Portfolio

Follow Alpha Mark Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Mark Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Mark Advisors, LLC with notifications on news.